Autolus Therapeutics Ltd – (NASDAQ:AUTL) has received a consensus rating of “Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $44.00.
A number of research firms have recently commented on AUTL. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Autolus Therapeutics in a research note on Friday, November 2nd. Wells Fargo & Co restated a “buy” rating and set a $50.00 price objective (up from $38.00) on shares of Autolus Therapeutics in a research note on Thursday. Finally, Zacks Investment Research downgraded shares of Autolus Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday.
Shares of NASDAQ AUTL opened at $39.02 on Friday. Autolus Therapeutics has a 1-year low of $19.17 and a 1-year high of $53.24.
Autolus Therapeutics Company Profile
Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Further Reading: What is a balanced fund?
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.